共 50 条
- [1] MBRC-101: a novel antibody-drug conjugate (ADC) targeting the tyrosine kinase receptor EphA5CANCER RESEARCH, 2024, 84 (06)Staquicini, Fernanda I.Tang, Fenny H.de Oliveira, VanessaStaquicini, Daniela I.Wu, YongjianBarnhart, Kirstin F.Parsons, J. KelloggArap, WadihChen, IsanPasqualini, Renata
- [2] Developing a novel doppel-targeting antibody-drug conjugate (ADC) for solid cancerCANCER RESEARCH, 2023, 83 (07)Lee, Ha KyeongKim, ByoungmoKweon, SehoChoi, Jeong UkKim, Sang YoonByun, Youngro
- [3] Vls-101 Is a Novel Therapeutic Antibody-Drug Conjugate (ADC) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Richter's Syndrome (RS)BLOOD, 2019, 134Vaisitti, TizianaJessen, KattiVo, Thanh-TrangKo, MiraArruga, FrancescaVitale, NicolettaBraggio, EstebanDi Napoli, AriannaChadburn, AmyAllan, John N.Furman, Richard R.Miller, Langdon L.Lanutti, Brian J.Deaglio, Silvia
- [4] Frequent epigenetic inactivation of the receptor tyrosine kinase EphA5 by promoter methylation in human breast cancerHUMAN PATHOLOGY, 2010, 41 (01) : 48 - 58Fu, De-YuanWang, Zhi-MinWang, Bei-LanChen, LiYang, Wen-TaoShen, Zhen-ZhouHuang, WeiShao, Zhi-Ming
- [5] Phase 1/1b Trial of MBRC-101, An Anti-EphA5 Monomethyl Auristatin (MMAE) Antibody Drug Conjugate, In Advanced Refractory Solid TumorsJOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S243 - S244Gubens, M.Sen, S.Salkeni, M. A.Vandross, A.Gandhi, N.Edenfield, W. J.Aggarwal, R.Parsons, K.Chen, I.Powderly, J.
- [6] Antibody-drug conjugates targeting RON receptor tyrosine kinase as a novel strategy for treatment of triple-negative breast cancerDRUG DISCOVERY TODAY, 2020, 25 (07) : 1160 - 1173Yao, Hang-PingSuthe, Sreedhar ReddyHudson, RachelWang, Ming-Hai
- [7] Receptor tyrosine kinase EphA5 is a functional molecular target in human lung cancerCANCER RESEARCH, 2015, 75Staquicini, FernandaDobroff, AndreyFerrara, FortunatoD'Angelo, SaraBradbury, Andrew R. M.Arap, WadihPasqualini, Renata
- [8] Receptor Tyrosine Kinase EphA5 Is a Functional Molecular Target in Human Lung CancerJOURNAL OF BIOLOGICAL CHEMISTRY, 2015, 290 (12) : 7345 - 7359Staquicini, Fernanda I.Qian, Ming D.Salameh, AhmadDobroff, Andrey S.Edwards, Julianna K.Cimino, Daniel F.Moeller, Benjamin J.Kelly, PatrickNunez, Maria I.Tang, XimingLiu, Diane D.Lee, J. JackHong, Waun KiFerrara, FortunatoBradbury, Andrew R. M.Lobb, Roy R.Edelman, Martin J.Sidman, Richard L.Wistuba, Ignacio I.Arap, WadihPasqualini, Renata
- [9] Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) studyJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Abelman, Rachel OcchiogrossoSpring, LauraFell, Geoffrey G.Ryan, PhoebeVidula, NeelimaMedford, Arielle J.Shin, JenniferIsakoff, Steven J.Moy, BeverlyEllisen, Leif W.Bardia, Aditya
- [10] A novel antibody-drug conjugate directed to the ALK receptor tyrosine kinase demonstrates efficacy in models of neuroblastomaCANCER RESEARCH, 2016, 76Sano, RenataKrytska, KaterynaLarmour, ColleenLigon, Gwenda F.Lillquist, Jay S.Cucchi, UlisseOrsini, PaoloRizzi, SimonaMcMahon, GeraldAlvarado, DiegoMosse, Yael P.